TVGN Insider Trading

Insider Ownership Percentage: 56.60%
Insider Buying (Last 12 Months): $2,460.00
Insider Selling (Last 12 Months): $1,747,332.00

Tevogen Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Tevogen Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tevogen Bio Share Price & Price History

Current Price: $1.01
Price Change: Price Decrease of -0.01 (-0.98%)
As of 12/12/2024 01:00 AM ET

This chart shows the closing price history over time for TVGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Tevogen Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/17/2024Neal FlomenbergInsiderSell1,078,600$1.62$1,747,332.004,254,302View SEC Filing Icon  
6/12/2024Kirti DesaiCFOBuy3,000$0.82$2,460.009,699,186View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2024Polar Asset Management Partners Inc.1,577,387$0.58M0.0%-20.6%0.924%Search for SEC Filing on Google Icon
11/15/2024HGC Investment Management Inc.223,077$82K0.0%N/A0.131%Search for SEC Filing on Google Icon
5/9/2024Portland Global Advisors LLC5,782,209$21.68M3.0%N/A36.550%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Tevogen Bio logo
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Read More on Tevogen Bio

Today's Range

Now: $1.01
Low: $0.98
High: $1.07

50 Day Range

MA: $1.44
Low: $0.26
High: $3.05

52 Week Range

Now: $1.01
Low: $0.26
High: $21.09

Volume

755,496 shs

Average Volume

2,689,809 shs

Market Capitalization

$176.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Tevogen Bio?

Tevogen Bio's top insider investors include:
  1. Kirti Desai (CFO)
  2. Neal Flomenberg (Insider)
Learn More about top insider investors at Tevogen Bio.

Who are the major institutional investors of Tevogen Bio?

Tevogen Bio's top institutional investors include:
  1. Polar Asset Management Partners Inc. — 0.92%
  2. HGC Investment Management Inc. — 0.13%
Learn More about top institutional investors of Tevogen Bio stock.

Which institutional investors are selling Tevogen Bio stock?

In the previous quarter, TVGN stock was sold by these institutional investors:
  1. Polar Asset Management Partners Inc.

Which institutional investors are buying Tevogen Bio stock?

During the last quarter, TVGN stock was acquired by institutional investors including:
  1. HGC Investment Management Inc.